Indirect‐response model for the time course of leukopenia with anticancer drugs
暂无分享,去创建一个
N. Saijo | K. Itoh | Y. Sasaki | T. Igarashi | H. Minami | N Saijo | T. Ohtsu | T Igarashi | T Ohtsu | Y Sasaki | H Minami | H Fujii | K Itoh | Hirofumi Fujii
[1] V P BOND,et al. GRANULOCYTOPOIESIS. II. EMERGENCE AND PATTERN OF LABELING OF NEUTROPHILIC GRANULOCYTES IN HUMANS. , 1964, Blood.
[2] M. Marty,et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.
[3] L B Sheiner,et al. A population model for the leukopenic effect of etoposide , 1995, Clinical pharmacology and therapeutics.
[4] L. Grochow,et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.
[5] W J Jusko,et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects , 1989, Clinical pharmacology and therapeutics.
[6] E. Endert,et al. Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. , 1984, The Journal of pharmacology and experimental therapeutics.
[7] George E. Cartwright,et al. Analytical Review: The Kinetics of Granulopoiesis in Normal Man , 1964 .
[8] W J Jusko,et al. Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.
[9] M. Egorin,et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. , 1984, Cancer research.
[10] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.
[11] R. Larsson,et al. A general model for time‐dissociated pharmacokinetic‐pharmacodynamic relationships exemplified by paclitaxel myelosuppression , 1998, Clinical pharmacology and therapeutics.
[12] D G Lowe,et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Ratain,et al. Modeling interpatient pharmacodynamic variability of etoposide. , 1991, Journal of the National Cancer Institute.
[14] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[15] H. Saka,et al. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. C. Dubbelman,et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L B Sheiner,et al. Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.
[18] K. Eguchi,et al. Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion , 1994, Japanese journal of cancer research : Gann.
[19] G. Bonadonna,et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Mauer,et al. LEUKOKINETIC STUDIES. II. A METHOD FOR LABELING GRANULOCYTES IN VITRO WITH RADIOACTIVE DIISOPROPYLFLUOROPHOSPHATE (DFP). , 1960, The Journal of clinical investigation.
[21] K. Shimokata,et al. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Schilsky,et al. Pharmacodynamics in cancer therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Egorin,et al. Paclitaxel pharmacokinetics and pharmacodynamics. , 1995, Seminars in oncology.
[24] Y. S. Sathe,et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.
[25] I. Boll,et al. Granulocytopoiesis in human bone marrow cultures studied by means of kinematography. , 1965, Blood.
[26] M. Ratain,et al. Individualizing dosing of cancer chemotherapy. , 1993, Seminars in oncology.
[27] M. Ratain,et al. Pharmacodynamic modeling of prolonged administration of etoposide , 1996, Cancer Chemotherapy and Pharmacology.
[28] P. Müller,et al. Pharmacodynamic analysis of hematologic profiles , 1994, Journal of Pharmacokinetics and Biopharmaceutics.
[29] M M WINTROBE,et al. THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN. , 1964, Blood.
[30] N. Saijo,et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] G. Levy,et al. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.